~~<i id='7E98B08C5B'><strike id='7E98B08C5B'><tt id='7E98B08C5B'><pre id='7E98B08C5B'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

entertainment

explore

author：explore 2025-10-02 00:51:43 - browse：87618

HHS 2020 — PhRMA is suing the Biden administration over its new Medicare drug price negotiation program. Graeme Sloan/Sipa USA

WASHINGTON — After losing the drug pricing fight on Capitol Hill, PhRMA is taking its battle to the courts.

The pharmaceutical industry’s biggest lobbying group on Wednesday filed a long-expected lawsuit challenging Democrats’ drug pricing law that allowed Medicare to start negotiating prices for certain medicines.

PhRMA joins a growing club of companies and trades challenging the law. Merck, Bristol Myers Squibb, and the Chamber of Commerce have already filed similar suits in different courts.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Pharmacists can make shortage drugs, but at what cost?

hotspot

focus

entertainment

hotspot

entertainment

hotspot

SurgicalinstrumentsandsupplieslayonatableduringakidneytransplantsurgeryatMedStarGeorgetownUniversity

WSS

NIH confirmation hearing shows politicization of research

STAT Summit: Biotech founders on deal

A public health expert passes on football's full body collisions for youths

Timeline: Key moments in fight for gay rights

Eli Lilly’s Mounjaro succeeds in second weight

Pharmacists can make shortage drugs, but at what cost?

entertainment

explore

hotspot

Sports medicine is finally prioritizing gender equality

Bispecific antibodies are next new thing in cancer immunotherapy

Drug repurposing or repositioning? The language matters

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

FDA approval of Sarepta Duchenne genetic therapy gives me hope

U.K. agency declines to back Eli Lilly’s Mounjaro for type 2 diabetes

Trump demands the U.S. pay no more for drugs than other countries … again

Beam Therapeutics to lay off 20% of its staff, re

Medical leaders decry Supreme Court decision on affirmative action

STAT Summit: GSK CEO on pharma giant's new direction

focus

Timeline: Key moments in fight for gay rights

Pharmacists can make shortage drugs, but at what cost?

Eli Lilly’s Mounjaro succeeds in second weight

Why health workers in Gaza are injured or die at high rates

Researchers explore possible ties between long Covid, menopause

STAT Readout Newsletter: Today's biggest biotech updates

entertainment

hotspot

entertainment

hotspot